DalsnaFinance

GEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver Diseases

Markets PR Newswire By PR Newswire 09 Jul 2026 17:06 1 min read
GEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver Diseases

- The goals of this project will be enabled through a partnership with Profluent Bio who will deploy its frontier AI models and its scalable base editor platform - GEMMABio will utilize a nonviral approach, encapsulating mRNA coding for Profluent's base-editing machinery into lipid...

- The goals of this project will be enabled through a partnership with Profluent Bio who will deploy its frontier AI models and its scalable base editor platform - GEMMABio will utilize a nonviral approach, encapsulating mRNA coding for Profluent's base-editing machinery into lipid...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.